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Abstract
Purpose—Pharmacoepidemiologic studies are often expected to be sufficiently powered to study 
rare outcomes, but there is sequential loss of power with implementation of study design options 
minimizing bias. We illustrate this using a study comparing pancreatic cancer incidence after 
initiating dipeptidyl-peptidase-4 inhibitors (DPP-4i) versus thiazolidinediones or sulfonylureas.
Methods—We identified Medicare beneficiaries with at least one claim of DPP-4i or 
comparators during 2007–2009 and then applied the following steps:1) Exclude prevalent users 2) 
Require a second prescription of same drug 3) Exclude prevalent cancers 4) Exclude patients age 
<66 years and 5) Censor for treatment changes during follow-up. Power to detect hazard ratios 
(effect measure strongly driven by the number of events) >=2.0 estimated after step 5 was 
compared with the naïve power estimated prior to step 1.
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Results—There were 19,388 and 28,846 DPP-4i and thiazolidinedione initiators during 2007–
2009. The number of drug initiators dropped most after requiring a second prescription, outcomes 
dropped most after excluding patients with prevalent cancer, and person-time dropped most after 
requiring a second prescription and as-treated censoring. The naïve power (>99%) was 
considerably higher than the power obtained after the final step (~75%).
Conclusions—In designing new-user active-comparator studies, one should be mindful how 
steps minimizing bias affect sample-size, number of outcomes, and person-time. While actual 
numbers will depend on specific settings, application of generic losses in percentages will improve 
estimates of power compared with the naive approach mostly ignoring steps taken to increase 
validity.
Keywords
New-user design; Power; Sample size; Bias
Introduction
Studies using large databases often provide large sample sizes1 and are therefore expected to 
be sufficiently powered to investigate rare outcomes. Power calculations included in study 
protocols based on the number of drug claims and outcomes in the database over a fixed 
time often do not take into account steps taken to increase the internal validity and therefore 
overestimate power considerably. Accounting for steps taken to minimize the potential for 
bias will yield more realistic power estimates, but this implies implementing most steps of 
the study, at which point power calculations are moot.
Power/precision is important while rating the quality of evidence from studies used for 
systematic reviews or clinical guidelines. The GRADE guidelines, for example, rate the 
evidence from under-powered observational studies as ‘very low quality’ and recommend 
rating down the quality of evidence by two levels in the presence of very few events and 
confidence intervals including both appreciable benefit and harm.2
We recently conducted a study comparing pancreatic cancer incidence with dipeptidyl-
peptidase-4 inhibitors (DPP-4i) versus sulfonylureas (SU) and thiazolidinediones (TZD) 
using Medicare claims data from 2007–2011.3 Preliminary power calculations suggested 
adequate DPP-4i prescriptions and pancreatic cancers in our datasets, but without data on 
treatment durations or censoring we were unable to estimate the mean follow-up, which led 
to considerable overestimation of the number of outcomes. This study demonstrates the loss 
of new-users, outcomes and person-time after each step taken to minimize bias. We first 
examined this for Medicare claims data from 2007–2009 and then validated these results 
with 2010–2012 data. We also report power calculations to detect a clinically meaningful 
increased hazard ratio of pancreatic cancer based on empirical estimates of follow-up time 
and other usual parameters.
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This study compared two new-user cohorts DPP-4i versus TZD and DPP-4i versus SU using 
a 20% random sample of Medicare beneficiaries aged >=66 years with fee-for-service Part 
A, B, D enrollment in at least one month during a calendar year from January 1, 2007 to 
December 31, 2011. Medicare covers >98% of US adults >=65 years and contains 
demographic, medical and pharmacy information for enrollees.4, 5
From this, we identified patients with at least one claim of DPP-4i or TZD/SU during 2007–
2009 and narrowed down to the final study cohort by excluding 1)Prevalent users of DPP-4i 
or comparator in the 6 months pre-initiation, 2)Patients without a second prescription of the 
same drug within 180 days post-initiation, 3)Patients with prevalent cancers, 4)Patients <66 
years and 5)Censor for treatment changes during follow-up. We aimed to examine whether 
pancreatic cancer incidence was higher among DPP-4i initiators relative to comparators, as 
assessed by the hazard ratio (HR). For HR, power depends strongly on the number of events, 
a function of the total number of new-users and person-time in each treatment cohort. This 
study reports the stepwise loss in the proportion of new-users, outcomes and person-time 
and compares power to detect literature based6 and clinically meaningful HR (>=2.0) before 
step 1 and after step 5 calculated using SAS 9.3.7,8 This process was validated with data 
from 2010–2012. We also applied empirical estimates of loss in percentages from 2007–
2009 data to estimate sample size, person-time and outcomes in the 2010–2012 data and 
compared the power calculated using empirical estimates with the actual power obtained 
using 2010–2012 data.
Results
During 2007–2009, there were 19,388 and 28,846 DPP-4i and TZD initiators respectively 
contributing 50,377 and 78,858 person-years. The mean age in the DPP-4i and TZD groups 
was 75.1 and 73.5 years. A naïve power calculation at this stage yielded a power of >99% to 
detect HR >=2.0.
The biggest drop in the proportion of new-users was after restricting to those with a second 
prescription of the same drug (~20 percentage points; table 1). Excluding prevalent cancers 
before the second prescription (~29 percentage points) was responsible for the biggest drop 
in outcomes. Major drops in person-time were due to the second prescription and as-treated 
censoring. The patterns of drop in percentages during 2010–2012 were very similar (table 
2). The power to detect a HR of 2.0 under as-treated analysis was 77% for 2007–2009 and 
72% for 2010–2012 which is considerably less than the naïve estimate at step 1. The power 
obtained with 2010–2012 data after applying the empirical estimates of loss in percentages 
from 2007–2009 data was 76% which is very close to the actual power obtained with the 
2010–2012 data (72%). Similar patterns were observed for the DPP versus SU 
(supplementary tables 1&2).
Discussion
We illustrate the stepwise loss of drug initiators, outcomes and person-time while 
implementing a new-user active-comparator study of pancreatic cancer incidence with 
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DPP-4i versus comparators. Major losses in the proportion of new-users and person-time 
occurred when the population was restricted to those having a second prescription of the 
drug, a criterion that increases the chance that the patients are actually started on the drug. 
The biggest drop in outcomes occurred after excluding individuals with evidence of 
prevalent cancers before the start of follow-up at the 2nd prescription. While we could have 
only excluded patients with pancreatic cancer at baseline (before the first prescription), 
cancer diagnoses/treatments between baseline and the start of follow-up might affect the risk 
for pancreatic cancer or the sensitivity and specificity of its diagnosis and therefore applied 
this criterion. Finally, the as-treated analysis reduced the outcomes and person-time leading 
to power estimates considerably less than estimated before step 1.
Statistical power of a study using secondary data is often overestimated at the study protocol 
stage based on easy-to-get pilot data on number of prescriptions and outcomes. While 
empirical data is preferred to estimate realistic power, this requires access to data and 
implementation of close to 100% of study steps, at which point power calculations are moot. 
Therefore, compared to naïve power calculations, our numbers at the protocol stage 
combined with rough estimates of number of prescriptions and incidence rates for the 
outcome in the population of interest should provide an approximation for studies that 
implement the steps of a new-user design in settings similar to ours. This is of particular 
relevance to studies comparing effects of diabetes treatments on incident cancers, a major 
focus of research.9–11 This does not imply a ‘one-size fits all’ approach to calculate power, 
however, and our method of comparing two survival curves will clearly not be generalizable 
to all other studies. Power calculations should always be based on the analysis methods 
selected to answer the question of interest. If relevant data can be obtained to implement 
more realistic power calculations, such data should obviously be used rather than our 
approximations.
Researchers should further be cognizant of additional decreases in power as a result of 
subgroup analyses, restriction and confounding control methods. Example, there could be 
substantial losses in the size of the comparator cohort due propensity score matching or in 
both treatment cohorts due to trimming the tails of propensity score distributions to reduce 
the potential for unmeasured confounding by frailty.12,13
Our study implies that researchers should be alert to the losses in available sample sizes and 
person-time with efforts to minimize bias. Similar logic would apply to often preferred 
measures related to the precision of the effect estimates (width or upper /lower limits of the 
confidence interval).14 We here focus on power solely because it is most often used at the 
study protocol stage without implying that we would encourage using statistical testing over 
reporting of point estimates and their precision.
A strength of our study was that estimates of treatment duration were based on our 
previously published study. A short treatment duration may be insufficient to observe a 
causal effect of a drug on cancer incidence because of the induction and latent periods.15 
Note that this issue is related to but not identical to person-time. While person-time can be 
increased by increasing the cohort size, the treatment duration will be mainly driven by 
actual treatment dynamics (in addition to restrictions of the database) and thus cannot be 
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addressed by increasing N. Accounting for empirical estimates of duration of treatment gave 
realistic power estimates and also allowed us to evaluate whether we had enough patients 
treated long enough to allow for an induction and latent period.
Our study had some caveats. First, we used an older Medicare population which has high 
diabetes prevalence and higher incidence of cancers compared to the general population. 
Therefore our numbers may not be directly applicable to other databases. However, using 
our numbers at the proposal stage combined with rough estimates of context-specific data on 
exposure and outcomes will provide a good alternative, compared to naïve power 
calculations. Second, the follow-up time used was the median follow-up in the DPP-4i 
group.3 Using the 75th percentile of follow-up time somewhat increased the power (~90%), 
but was still lower than the naïve estimates.
In summary, while designing new-user active-comparator studies, one should be mindful 
how steps to minimize the potential for bias affect sample size, outcomes and person-time at 
risk. Our results may be particularly helpful to derive realistic estimates of power (or 
precision) while designing robust studies comparing rare outcomes for antihyperglycemic 
drugs or other settings with additional context-specific data.
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Example SAS code for power calculations
*DPP vs TZD 2007 – 2009;
proc power;
twosamplesurvival test=logrank
      curve("unexposed")= 1:0.998 2:0.996 3:0.995 /* based on the kaplan 
meier curve. time:survival at various points in the TZD group*/
      refsurvival = "unexposed"
      hazardratio = 2.0 /*power to detect hazard ratio of 2.0 */
       accrualtime = 0.01 /* time during which subjects are recruited in 
the study. Set to a minimal non-zero value 0.01 since we are not 
recruiting/accruing any subjects*/
      followuptime = 0.8 /*median followup time in the data */
      groupns = 19388|28846 /* number of new users in TZD and DPP groups 
respectively*/
      power = .;
run;
Gokhale et al. Page 7














• In pharmacoepidemiologic studies, the power or sample size estimates reported 
in the study protocol based on easy-to-get pilot data are often naïve because they 
ignore the study design steps implemented to minimize the potential for bias.
• This study illustrates the stepwise loss of drug initiators, outcomes, person-time 
while implementing a new-user active-comparator cohort study of pancreatic 
cancer incidence with dipeptidyl-peptidase-4 inhibitors (DPP-4i) versus 
thiazolidinediones (TZD) or sulfonylureas (SU).
• In a population of Medicare enrollees >= 66 years of age, the biggest drop in 
sample size occurred with requiring a second prescription of the same drug; the 
biggest drop in number of outcomes occurred after excluding patients with 
prevalent cancer; the biggest drops in person-time occurred after requiring a 
second prescription and as-treated censoring for treatment changes. The naïve 
statistical power to detect hazard ratio >= 2.0 was considerably higher (>99%) 
than the power obtained at the final step (~75%) for both cohorts.
• Our results are of particular relevance for studies comparing the effect of 
diabetes treatments on incident cancers. While actual numbers will depend on 
the specific setting, application of generic percentages of loss in sample size and 
person-time will improve power estimates in other studies comparing outcomes 
for antihyperglycemic drugs and, most likely, also other studies with context-
specific data compared with the naïve approach ignoring the effects of study 
design to improve validity on power and sample size.
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